413
Views
27
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

A microRNA meta-signature for pancreatic ductal adenocarcinoma

, , , , , , & show all

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Tessa Y.S. Le Large, Laura L. Meijer, Mireia Mato Prado, Geert Kazemier, Adam E. Frampton & Elisa Giovannetti. (2015) Circulating microRNAs as diagnostic biomarkers for pancreatic cancer. Expert Review of Molecular Diagnostics 15:12, pages 1525-1529.
Read now

Articles from other publishers (26)

Christian Prinz, Leonard Fehring & Robin Frese. (2022) MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions. Cells 11:15, pages 2374.
Crossref
Monica Valente, Alessia Covre, Anna Maria Di Giacomo & Michele Maio. 2022. Hepato-Pancreato-Biliary Malignancies. Hepato-Pancreato-Biliary Malignancies 761 776 .
Konstantin Schlick, Dominik Kiem & Richard Greil. (2021) Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy—A Review of the Literature. Biomolecules 11:10, pages 1469.
Crossref
Beste Turanli, Esra Yildirim, Gizem Gulfidan, Kazim Yalcin Arga & Raghu Sinha. (2021) Current State of “Omics” Biomarkers in Pancreatic Cancer. Journal of Personalized Medicine 11:2, pages 127.
Crossref
Monica Valente, Alessia Covre, Anna Maria Di Giacomo & Michele Maio. 2021. Hepato-Pancreato-Biliary Malignancies. Hepato-Pancreato-Biliary Malignancies 1 17 .
Yong-Qiang Hua, Yao-Dong Zhu, Guo-Qun Xie, Ke Zhang, Jie Sheng, Zhen-Feng Zhu, Zhou-Yu Ning, Hao Chen, Zhen Chen, Zhi-Qiang Meng & Lu-Ming Liu. (2019) Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1. Aging 11:20, pages 8860-8878.
Crossref
Rawat, Kadian, Gupta, Kumar, Chain, Kovbasnjuk, Kumar & Parasher. (2019) MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential. Genes 10:10, pages 752.
Crossref
Natalia Anahi Juiz, Juan Iovanna & Nelson Dusetti. (2019) Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome. Frontiers in Oncology 9.
Crossref
Sachiyo Kawamura, Hisae Iinuma, Keita Wada, Kunihiko Takahashi, Shunryo Minezaki, Masahiko Kainuma, Makoto Shibuya, Fumihiko Miura & Keiji Sano. (2019) Exosome‐encapsulated microRNA‐4525, microRNA‐451a and microRNA‐21 in portal vein blood is a high‐sensitive liquid biomarker for the selection of high‐risk pancreatic ductal adenocarcinoma patients. Journal of Hepato-Biliary-Pancreatic Sciences 26:2, pages 63-72.
Crossref
Jens C. Hahne & Nicola Valeri. (2018) Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors. Frontiers in Oncology 8.
Crossref
Xiao Sun, Xiaobin Zhou, Yuan Zhang, Xiaoyan Zhu & Haihua Liu. (2018) Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer. Disease Markers 2018, pages 1-13.
Crossref
Dan Calatayud, Christian Dehlendorff, Mogens K. Boisen, Jane Preuss Hasselby, Nicolai Aagaard Schultz, Jens Werner, Heike Immervoll, Anders Molven, Carsten Palnæs Hansen & Julia S. Johansen. (2017) Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Biomarker Research 5:1.
Crossref
Shinichi Kanno, Katsuhiko Nosho, Keisuke Ishigami, Itaru Yamamoto, Hideyuki Koide, Hiroyoshi Kurihara, Kei Mitsuhashi, Masahiro Shitani, Masayo Motoya, Shigeru Sasaki, Tokuma Tanuma, Hiroyuki Maguchi, Tadashi Hasegawa, Yasutoshi Kimura, Ichiro Takemasa, Yasuhisa Shinomura & Hiroshi Nakase. (2017) MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer. Carcinogenesis 38:4, pages 425-431.
Crossref
Přemysl Frič, Jan Škrha, Aleksi Šedo, Tomaš Zima, Petr Bušek, Klára Kmochová, Martin Laclav, Bohuš Bunganič, Svatopluk Solař, Petr Hrabal, František Bělina, Pavel Záruba, Pavel Škrha & Miroslav Zavoral. (2016) Early detection of pancreatic cancer. European Journal of Gastroenterology & Hepatology 28:12, pages e33-e43.
Crossref
Karen M. Mann, Haoqiang Ying, Joseph Juan, Nancy A. Jenkins & Neal G. Copeland. (2016) KRAS-related proteins in pancreatic cancer. Pharmacology & Therapeutics 168, pages 29-42.
Crossref
Christina Vorvis, Marina Koutsioumpa & Dimitrios Iliopoulos. (2016) Developments in miRNA gene signaling pathways in pancreatic cancer. Future Oncology 12:9, pages 1135-1150.
Crossref
Katsuhiko Nosho. (2016) Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer . World Journal of Gastroenterology 22:2, pages 557.
Crossref
Ingrid Garajová, Niccola Funel, Michelangelo Fiorentino, Valentina Agostini, Manuela Ferracin, Massimo Negrini, Giovanni Luca Frassineti, Giampaolo Gavelli, Adam Enver Frampton, Guido Biasco & Elisa Giovannetti. (2015) MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma—a step towards personalized therapy. Clinical Epigenetics 7:1.
Crossref
Michela Visani, Giorgia Acquaviva, Sirio Fiorino, Maria Letizia Bacchi Reggiani, Michele Masetti, Enrico Franceschi, Adele Fornelli, Elio Jovine, Carlo Fabbri, Alba A Brandes, Giovanni Tallini, Annalisa Pession & Dario de Biase. (2015) Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. Journal of Clinical Pathology 68:11, pages 859-869.
Crossref
ZHENGHAI BAI, JIANGLI SUN, XIAOBO WANG, HAI WANG, HONGHONG PEI & ZHENGLIANG ZHANG. (2015) MicroRNA-153 is a prognostic marker and inhibits cell migration and invasion by targeting SNAI1 in human pancreatic ductal adenocarcinoma. Oncology Reports 34:2, pages 595-602.
Crossref
Ingrid Garajová, Elisa Giovannetti, Sara Caponi, Annette van Zweeden & Godefridus J. Peters. (2015) MiRNAs and Their Interference with the Main Molecular Mechanisms Responsible for Drug Resistance in Pancreatic Cancer. Current Pharmacology Reports 1:4, pages 223-233.
Crossref
Christopher L Pin, Joanna F Ryan & Rashid Mehmood. (2015) Acinar cell reprogramming: a clinically important target in pancreatic disease. Epigenomics 7:2, pages 267-281.
Crossref
Kei Mitsuhashi, Katsuhiko Nosho, Yasutaka Sukawa, Yasutaka Matsunaga, Miki Ito, Hiroyoshi Kurihara, Shinichi Kanno, Hisayoshi Igarashi, Takafumi Naito, Yasushi Adachi, Mami Tachibana, Tokuma Tanuma, Hiroyuki Maguchi, Toshiya Shinohara, Tadashi Hasegawa, Masafumi Imamura, Yasutoshi Kimura, Koichi Hirata, Reo Maruyama, Hiromu Suzuki, Kohzoh Imai, Hiroyuki Yamamoto & Yasuhisa Shinomura. (2015) Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis . Oncotarget 6:9, pages 7209-7220.
Crossref
Xavier Bofill-De Ros, Eneko Villanueva & Cristina Fillat. (2015) Late-phase miRNA-controlled oncolytic adenovirus for selective killing of cancer cells. Oncotarget 6:8, pages 6179-6190.
Crossref
Satyanarayana Rachagani, Muzafar A. Macha, Nicholas Heimann, Parthasarathy Seshacharyulu, Dhanya Haridas, Seema Chugh & Surinder K. Batra. (2015) Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Advanced Drug Delivery Reviews 81, pages 16-33.
Crossref
Ingrid Garajová, Tessa Y. Le Large, Adam E. Frampton, Christian Rolfo, Johannes Voortman & Elisa Giovannetti. (2014) Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer. BioMed Research International 2014, pages 1-17.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.